胰腺癌是世界上第二常见的胃肠癌症，但不到5％的5年生存率迫切需要改善胰腺癌的医学干预。目前，高剂量放射治疗（RT）被用作辅助治疗；然而，用于治疗晚期肿瘤所需的高水平放疗会导致高发生率的副作用。近年来，细胞因子作为放射增敏剂的利用已经被研究，以减少所需放射线的剂量。然而，很少有研究考察过IL-28作为放射增敏剂的潜力。此研究是第一个利用IL-28作为胰腺癌放射增敏剂的研究，该研究中使用了广泛的胰腺癌细胞系MiaPaCa-2。对MiaPaCa-2细胞的增长、增殖进行了克隆生存和细胞增殖实验。使用Caspase-3活性测定法评估了MiaPaCa-2的细胞凋亡，使用RT-PCR研究了可能的分子机制。我们的研究结果表明，IL-28/RT增强了RT对MiaPaCa-2细胞增殖的抑制作用，并促进了细胞凋亡。此外，与单独使用RT相比，我们发现IL-28/RT上调了MiaPaCa-2细胞中TRAILR1和P21的mRNA表达，同时下调了P18和survivin的mRNA表达。IL-28具有作为胰腺癌放射增敏剂的潜力，值得进一步研究。版权所有 © 2023 International Institute of Anticancer Research（George J.Delinasios博士），保留所有权利。

Pancreatic cancer is the second most common gastrointestinal cancer in the world, yet the five-year survival outcome rate of less than 5% urges for improvement in medical interventions of pancreatic cancer. Currently, high dose radiation therapy (RT) is used as an adjuvant treatment; however, the high level of RT required to treat advanced neoplasms leads to high incidence rates of side effects. In recent years, the utilization of cytokines as radiosensitizing agents has been studied, in order to reduce the amount of radiation required. However, few studies have examined IL-28 regarding its potential as a radiosensitizer. This study is the first to utilize IL-28 as a radiosensitizing agent in pancreatic cancer.MiaPaCa-2, a widely used pancreatic cancer cell line was used in this study. Clonogenic survival and cell proliferation assays were used to evaluate growth and proliferation of MiaPaCa-2 cells. Caspase-3 activity assay was used to evaluate apoptosis of MiaPaCa-2 cells and RT-PCR was used to study the possible molecular mechanisms.Our results showed that IL-28/RT enhanced RT-induced inhibition of cell proliferation and promoted apoptosis of MiaPaCa-2 cells. Furthermore, compared to RT alone, we found that IL-28/RT up-regulated the mRNA expression of TRAILR1 and P21, while down-regulating mRNA expression of P18 and survivin in MiaPaCa-2 cells.IL-28 has the potential to be used as a radiosensitizer for pancreatic cancer and warrants further investigation.Copyright © 2023 International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.